Indivior Plc
INDV
Market Cap$2.89B
Close$
$-8.12
167.5% downside
Current Fair Value
167.5% downsideOvervalued by 167.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.89 Billion |
|---|---|
| Enterprise Value | $2.59 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.01 |
| Beta | 0.2 |
| Outstanding Shares | 134,848,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.31 |
|---|---|
| PEG | 10 |
| Price to Sales | 1.51 |
| Price to Book Ratio | -4.01 |
| Enterprise Value to Revenue | 2.18 |
| Enterprise Value to EBIT | 14.21 |
| Enterprise Value to Net Income | -1169 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...